Genable Technologies, an early-stage Irish biotechnology company, has raised €1.1 million in an investment round led by the venture capital firm Delta Partners.

The firm, which is located at Trinity College Dublin, is developing gene-based therapies for the treatment of incurable inherited diseases such as retinitis pigmentosa, brittle bone disease and Huntington's chorea.

It recently accelerated its development programme for retinitis pigmentosa, an inherited disease affecting the retina at the back of the eye, which is estimated to affect about 345,000 people worldwide.

Genable's technology platform provides for the suppression and replacement of genes. Developed from over 10 years of research, it is now entering into pre-clinical studies, the company said yesterday.